Prosecution Insights
Last updated: August 18, 2026

Examiner: PIHONAK, SARAH

Tech Center 1600 • Art Units: 1617 1627

This examiner grants 61% of resolved cases

Performance Statistics

61.1%
Allow Rate
+1.1% vs TC avg
1,540
Total Applications
+42.9%
Interview Lift
1028
Avg Prosecution Days
Based on 1500 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
10.2%
§102 Novelty
39.4%
§103 Obviousness
23.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18548797 METHOD OF INCREASING THE POPULATION OF BLAUTIA SPP. IN THE GUT MICROBIOME Non-Final OA DSM IP Assets B.V.
18278904 COMPOUNDS AND METHODS FOR TREATING CONGENITAL ERYTHROPOIETIC PORPHYRIA Non-Final OA REGENTS OF THE UNIVERSITY OF MICHIGAN
18237360 METALLOENZYME MODULATORS Non-Final OA Regents of the University of Minnesota
18579786 COMPOSITIONS COMPRISING CONSTITUENTS, DERIVATIVES OR EXTRACTS OF CANNABIS Non-Final OA Nicoventures Trading Limited
18040515 METHODS AND COMPOSITIONS FOR TREATING CYTOKINE RELEASE SYNDROME Final Rejection Temple University-Of The Commonwealth System of Higher Education
18630898 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Non-Final OA UNION therapeutics A/S
18037405 COMPOSITIONS AND METHODS FOR TREATING PULMONARY FIBROSIS Final Rejection Pulmosim Therapeutics LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month